Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family
Summary The role of epigenetic mechanisms in the regulation of microRNAs (miRNAs) with a tumour‐suppressor function in human neoplasms has recently been established. Several miRNAs have been found to be inappropriately regulated by DNA methylation in patients with acute lymphoblastic leukaemia (ALL)...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2011-10, Vol.155 (1), p.73-83 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 83 |
|---|---|
| container_issue | 1 |
| container_start_page | 73 |
| container_title | British journal of haematology |
| container_volume | 155 |
| creator | Rodriguez‐Otero, Paula Román‐Gómez, José Vilas‐Zornoza, Amaia José‐Eneriz, Edurne San Martín‐Palanco, Vanesa Rifón, José Torres, Antonio Calasanz, María José Agirre, Xabier Prosper, Felipe |
| description | Summary
The role of epigenetic mechanisms in the regulation of microRNAs (miRNAs) with a tumour‐suppressor function in human neoplasms has recently been established. Several miRNAs have been found to be inappropriately regulated by DNA methylation in patients with acute lymphoblastic leukaemia (ALL). We analysed the methylation status of the three members of the MIR9 family (MIR9‐1, MIR9‐2 and MIR9‐3) in a uniformly treated cohort of 200 newly diagnosed ALLs. MIR9 was methylated in 54% of the patients and was associated with downregulation of MIR9 (P |
| doi_str_mv | 10.1111/j.1365-2141.2011.08812.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920787936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>920787936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4802-3a452ff3739fa76e506b64aeda6d1d00f8687867fbcf7afe56a4abf7292331b63</originalsourceid><addsrcrecordid>eNqNkc1u1DAURi0EosPAKyBvEKsE_ySOs2ABU6YtFCFVsLZuHHvGgxOncaI2j8Bbk3SGsgQvbEvfuf4sHYQwJSmd17tDSrnIE0YzmjJCaUqkpCy9f4JWj8FTtCKEFAklmTxDL2I8EEI5yelzdMaopISUbIV-nZve7EYPgwstDhZvL7Y3FENb4835F4FDq8POtE7jDob9HUwRuxaDHgeD_dR0-1B5iMOcezP-BNM4wHvoqzD2rt1h07l52ix5E2pnnX4oikvTsDf469VNiS00zk8v0TMLPppXp3ONfmw_fd9cJtffLq42H64TnUnCEg5ZzqzlBS8tFMLkRFQiA1ODqGlNiJVCFlIUttK2AGtyARlUtmAl45xWgq_R2-O7XR9uRxMH1biojffQmjBGVTJSyKLk_yallJyLct7WSB5J3YcYe2NV17sG-klRohZj6qAWMWoRoxZj6sGYup9HX59Kxqox9ePgH0Uz8OYEQNTgbQ-tdvEvl-Uil7PZNXp_5O6cN9N_f0B9_Hy53PhvKNCyJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>888336983</pqid></control><display><type>article</type><title>Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Rodriguez‐Otero, Paula ; Román‐Gómez, José ; Vilas‐Zornoza, Amaia ; José‐Eneriz, Edurne San ; Martín‐Palanco, Vanesa ; Rifón, José ; Torres, Antonio ; Calasanz, María José ; Agirre, Xabier ; Prosper, Felipe</creator><creatorcontrib>Rodriguez‐Otero, Paula ; Román‐Gómez, José ; Vilas‐Zornoza, Amaia ; José‐Eneriz, Edurne San ; Martín‐Palanco, Vanesa ; Rifón, José ; Torres, Antonio ; Calasanz, María José ; Agirre, Xabier ; Prosper, Felipe</creatorcontrib><description>Summary
The role of epigenetic mechanisms in the regulation of microRNAs (miRNAs) with a tumour‐suppressor function in human neoplasms has recently been established. Several miRNAs have been found to be inappropriately regulated by DNA methylation in patients with acute lymphoblastic leukaemia (ALL). We analysed the methylation status of the three members of the MIR9 family (MIR9‐1, MIR9‐2 and MIR9‐3) in a uniformly treated cohort of 200 newly diagnosed ALLs. MIR9 was methylated in 54% of the patients and was associated with downregulation of MIR9 (P < 0·01). Hypermethylation of MIR9 was an independent prognostic factor for disease‐free survival, overall survival and event‐free survival in a multivariate analysis (P < 0·01). Epigenetic downregulation of MIR9 induced upregulation of its targets, FGFR1 and CDK6, while treatment of ALL cells with FGFR1 (PD‐173074) and CDK6 (PD‐0332991) inhibitors induced a decrease in cell proliferation and an increase in apoptosis of ALL cells. Our results indicate that the MIR9 family is involved in the pathogenesis and clinical behaviour of ALL and provide the basis for new therapeutic strategies in the treatment of ALL, targeting the epigenetic regulation of miRNAs and/or the FGFR1 or CDK6‐RB pathway directly.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2011.08812.x</identifier><identifier>PMID: 21810092</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Acute lymphatic leukemia ; acute lymphoblastic leukaemia ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Biological and medical sciences ; Cell proliferation ; Cell Proliferation - drug effects ; Child ; Child, Preschool ; Chromosome Aberrations ; CpG Islands - genetics ; Cyclin-Dependent Kinase 6 - antagonists & inhibitors ; Cyclin-Dependent Kinase 6 - biosynthesis ; Cyclin-Dependent Kinase 6 - genetics ; DNA Methylation ; DNA, Neoplasm - genetics ; Down-Regulation ; Epigenesis, Genetic ; epigenetics ; Female ; Fibroblast growth factor receptor 1 ; Gene Expression Regulation, Neoplastic ; Hematologic and hematopoietic diseases ; Humans ; Infant ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; microRNAs ; MicroRNAs - genetics ; MicroRNAs - physiology ; Middle Aged ; MIR9 ; miRNA ; Multivariate analysis ; oncogenic pathways ; Piperazines - pharmacology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Prognosis ; Pyridines - pharmacology ; Pyrimidines - pharmacology ; Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors ; Receptor, Fibroblast Growth Factor, Type 1 - biosynthesis ; Receptor, Fibroblast Growth Factor, Type 1 - genetics ; RNA, Neoplasm - genetics ; RNA, Neoplasm - physiology ; Signal Transduction - drug effects ; Tumor Cells, Cultured ; Young Adult</subject><ispartof>British journal of haematology, 2011-10, Vol.155 (1), p.73-83</ispartof><rights>2011 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2011 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4802-3a452ff3739fa76e506b64aeda6d1d00f8687867fbcf7afe56a4abf7292331b63</citedby><cites>FETCH-LOGICAL-c4802-3a452ff3739fa76e506b64aeda6d1d00f8687867fbcf7afe56a4abf7292331b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2011.08812.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2011.08812.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24565801$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21810092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodriguez‐Otero, Paula</creatorcontrib><creatorcontrib>Román‐Gómez, José</creatorcontrib><creatorcontrib>Vilas‐Zornoza, Amaia</creatorcontrib><creatorcontrib>José‐Eneriz, Edurne San</creatorcontrib><creatorcontrib>Martín‐Palanco, Vanesa</creatorcontrib><creatorcontrib>Rifón, José</creatorcontrib><creatorcontrib>Torres, Antonio</creatorcontrib><creatorcontrib>Calasanz, María José</creatorcontrib><creatorcontrib>Agirre, Xabier</creatorcontrib><creatorcontrib>Prosper, Felipe</creatorcontrib><title>Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
The role of epigenetic mechanisms in the regulation of microRNAs (miRNAs) with a tumour‐suppressor function in human neoplasms has recently been established. Several miRNAs have been found to be inappropriately regulated by DNA methylation in patients with acute lymphoblastic leukaemia (ALL). We analysed the methylation status of the three members of the MIR9 family (MIR9‐1, MIR9‐2 and MIR9‐3) in a uniformly treated cohort of 200 newly diagnosed ALLs. MIR9 was methylated in 54% of the patients and was associated with downregulation of MIR9 (P < 0·01). Hypermethylation of MIR9 was an independent prognostic factor for disease‐free survival, overall survival and event‐free survival in a multivariate analysis (P < 0·01). Epigenetic downregulation of MIR9 induced upregulation of its targets, FGFR1 and CDK6, while treatment of ALL cells with FGFR1 (PD‐173074) and CDK6 (PD‐0332991) inhibitors induced a decrease in cell proliferation and an increase in apoptosis of ALL cells. Our results indicate that the MIR9 family is involved in the pathogenesis and clinical behaviour of ALL and provide the basis for new therapeutic strategies in the treatment of ALL, targeting the epigenetic regulation of miRNAs and/or the FGFR1 or CDK6‐RB pathway directly.</description><subject>Acute lymphatic leukemia</subject><subject>acute lymphoblastic leukaemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cell proliferation</subject><subject>Cell Proliferation - drug effects</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chromosome Aberrations</subject><subject>CpG Islands - genetics</subject><subject>Cyclin-Dependent Kinase 6 - antagonists & inhibitors</subject><subject>Cyclin-Dependent Kinase 6 - biosynthesis</subject><subject>Cyclin-Dependent Kinase 6 - genetics</subject><subject>DNA Methylation</subject><subject>DNA, Neoplasm - genetics</subject><subject>Down-Regulation</subject><subject>Epigenesis, Genetic</subject><subject>epigenetics</subject><subject>Female</subject><subject>Fibroblast growth factor receptor 1</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>microRNAs</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - physiology</subject><subject>Middle Aged</subject><subject>MIR9</subject><subject>miRNA</subject><subject>Multivariate analysis</subject><subject>oncogenic pathways</subject><subject>Piperazines - pharmacology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Prognosis</subject><subject>Pyridines - pharmacology</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors</subject><subject>Receptor, Fibroblast Growth Factor, Type 1 - biosynthesis</subject><subject>Receptor, Fibroblast Growth Factor, Type 1 - genetics</subject><subject>RNA, Neoplasm - genetics</subject><subject>RNA, Neoplasm - physiology</subject><subject>Signal Transduction - drug effects</subject><subject>Tumor Cells, Cultured</subject><subject>Young Adult</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAURi0EosPAKyBvEKsE_ySOs2ABU6YtFCFVsLZuHHvGgxOncaI2j8Bbk3SGsgQvbEvfuf4sHYQwJSmd17tDSrnIE0YzmjJCaUqkpCy9f4JWj8FTtCKEFAklmTxDL2I8EEI5yelzdMaopISUbIV-nZve7EYPgwstDhZvL7Y3FENb4835F4FDq8POtE7jDob9HUwRuxaDHgeD_dR0-1B5iMOcezP-BNM4wHvoqzD2rt1h07l52ix5E2pnnX4oikvTsDf469VNiS00zk8v0TMLPppXp3ONfmw_fd9cJtffLq42H64TnUnCEg5ZzqzlBS8tFMLkRFQiA1ODqGlNiJVCFlIUttK2AGtyARlUtmAl45xWgq_R2-O7XR9uRxMH1biojffQmjBGVTJSyKLk_yallJyLct7WSB5J3YcYe2NV17sG-klRohZj6qAWMWoRoxZj6sGYup9HX59Kxqox9ePgH0Uz8OYEQNTgbQ-tdvEvl-Uil7PZNXp_5O6cN9N_f0B9_Hy53PhvKNCyJw</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Rodriguez‐Otero, Paula</creator><creator>Román‐Gómez, José</creator><creator>Vilas‐Zornoza, Amaia</creator><creator>José‐Eneriz, Edurne San</creator><creator>Martín‐Palanco, Vanesa</creator><creator>Rifón, José</creator><creator>Torres, Antonio</creator><creator>Calasanz, María José</creator><creator>Agirre, Xabier</creator><creator>Prosper, Felipe</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>201110</creationdate><title>Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family</title><author>Rodriguez‐Otero, Paula ; Román‐Gómez, José ; Vilas‐Zornoza, Amaia ; José‐Eneriz, Edurne San ; Martín‐Palanco, Vanesa ; Rifón, José ; Torres, Antonio ; Calasanz, María José ; Agirre, Xabier ; Prosper, Felipe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4802-3a452ff3739fa76e506b64aeda6d1d00f8687867fbcf7afe56a4abf7292331b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute lymphatic leukemia</topic><topic>acute lymphoblastic leukaemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cell proliferation</topic><topic>Cell Proliferation - drug effects</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chromosome Aberrations</topic><topic>CpG Islands - genetics</topic><topic>Cyclin-Dependent Kinase 6 - antagonists & inhibitors</topic><topic>Cyclin-Dependent Kinase 6 - biosynthesis</topic><topic>Cyclin-Dependent Kinase 6 - genetics</topic><topic>DNA Methylation</topic><topic>DNA, Neoplasm - genetics</topic><topic>Down-Regulation</topic><topic>Epigenesis, Genetic</topic><topic>epigenetics</topic><topic>Female</topic><topic>Fibroblast growth factor receptor 1</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>microRNAs</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - physiology</topic><topic>Middle Aged</topic><topic>MIR9</topic><topic>miRNA</topic><topic>Multivariate analysis</topic><topic>oncogenic pathways</topic><topic>Piperazines - pharmacology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Prognosis</topic><topic>Pyridines - pharmacology</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors</topic><topic>Receptor, Fibroblast Growth Factor, Type 1 - biosynthesis</topic><topic>Receptor, Fibroblast Growth Factor, Type 1 - genetics</topic><topic>RNA, Neoplasm - genetics</topic><topic>RNA, Neoplasm - physiology</topic><topic>Signal Transduction - drug effects</topic><topic>Tumor Cells, Cultured</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodriguez‐Otero, Paula</creatorcontrib><creatorcontrib>Román‐Gómez, José</creatorcontrib><creatorcontrib>Vilas‐Zornoza, Amaia</creatorcontrib><creatorcontrib>José‐Eneriz, Edurne San</creatorcontrib><creatorcontrib>Martín‐Palanco, Vanesa</creatorcontrib><creatorcontrib>Rifón, José</creatorcontrib><creatorcontrib>Torres, Antonio</creatorcontrib><creatorcontrib>Calasanz, María José</creatorcontrib><creatorcontrib>Agirre, Xabier</creatorcontrib><creatorcontrib>Prosper, Felipe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodriguez‐Otero, Paula</au><au>Román‐Gómez, José</au><au>Vilas‐Zornoza, Amaia</au><au>José‐Eneriz, Edurne San</au><au>Martín‐Palanco, Vanesa</au><au>Rifón, José</au><au>Torres, Antonio</au><au>Calasanz, María José</au><au>Agirre, Xabier</au><au>Prosper, Felipe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2011-10</date><risdate>2011</risdate><volume>155</volume><issue>1</issue><spage>73</spage><epage>83</epage><pages>73-83</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
The role of epigenetic mechanisms in the regulation of microRNAs (miRNAs) with a tumour‐suppressor function in human neoplasms has recently been established. Several miRNAs have been found to be inappropriately regulated by DNA methylation in patients with acute lymphoblastic leukaemia (ALL). We analysed the methylation status of the three members of the MIR9 family (MIR9‐1, MIR9‐2 and MIR9‐3) in a uniformly treated cohort of 200 newly diagnosed ALLs. MIR9 was methylated in 54% of the patients and was associated with downregulation of MIR9 (P < 0·01). Hypermethylation of MIR9 was an independent prognostic factor for disease‐free survival, overall survival and event‐free survival in a multivariate analysis (P < 0·01). Epigenetic downregulation of MIR9 induced upregulation of its targets, FGFR1 and CDK6, while treatment of ALL cells with FGFR1 (PD‐173074) and CDK6 (PD‐0332991) inhibitors induced a decrease in cell proliferation and an increase in apoptosis of ALL cells. Our results indicate that the MIR9 family is involved in the pathogenesis and clinical behaviour of ALL and provide the basis for new therapeutic strategies in the treatment of ALL, targeting the epigenetic regulation of miRNAs and/or the FGFR1 or CDK6‐RB pathway directly.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21810092</pmid><doi>10.1111/j.1365-2141.2011.08812.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2011-10, Vol.155 (1), p.73-83 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_920787936 |
| source | MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Acute lymphatic leukemia acute lymphoblastic leukaemia Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Biological and medical sciences Cell proliferation Cell Proliferation - drug effects Child Child, Preschool Chromosome Aberrations CpG Islands - genetics Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - biosynthesis Cyclin-Dependent Kinase 6 - genetics DNA Methylation DNA, Neoplasm - genetics Down-Regulation Epigenesis, Genetic epigenetics Female Fibroblast growth factor receptor 1 Gene Expression Regulation, Neoplastic Hematologic and hematopoietic diseases Humans Infant Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences microRNAs MicroRNAs - genetics MicroRNAs - physiology Middle Aged MIR9 miRNA Multivariate analysis oncogenic pathways Piperazines - pharmacology Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Pyridines - pharmacology Pyrimidines - pharmacology Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 1 - biosynthesis Receptor, Fibroblast Growth Factor, Type 1 - genetics RNA, Neoplasm - genetics RNA, Neoplasm - physiology Signal Transduction - drug effects Tumor Cells, Cultured Young Adult |
| title | Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A15%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deregulation%20of%20FGFR1%20and%20CDK6%20oncogenic%20pathways%20in%20acute%20lymphoblastic%20leukaemia%20harbouring%20epigenetic%20modifications%20of%20the%20MIR9%20family&rft.jtitle=British%20journal%20of%20haematology&rft.au=Rodriguez%E2%80%90Otero,%20Paula&rft.date=2011-10&rft.volume=155&rft.issue=1&rft.spage=73&rft.epage=83&rft.pages=73-83&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2011.08812.x&rft_dat=%3Cproquest_cross%3E920787936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=888336983&rft_id=info:pmid/21810092&rfr_iscdi=true |